TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
2'-OMe-C(Ac) Phosphoramidites are 2'-modified phosphoramidite monomers that serve as essential building blocks for the synthesis of antisense oligonucleotides, siRNA and mRNA therapeutics, enabling enhanced nuclease resistance and target affinity.
Demand is propelled by the rapid growth of RNA‑based drug pipelines, increased outsourcing of custom synthesis, and the push for higher‑purity (>98%) reagents to meet stringent regulatory expectations.
Looking ahead, manufacturers are expected to expand capacity, invest in automated synthesis platforms, and pursue strategic partnerships to capture emerging opportunities across biotech and research laboratories worldwide.
Global 2'-OMe-C(Ac) Phosphoramidites market was valued at USD 150 million in 2025 and is projected to reach USD 300 million by 2034, at a CAGR of 7.9% during the forecast period. 2'-OMe-C(Ac) Phosphoramidite is a 2'-modified phosphoramidite monomer that serves as an oligonucleotide building block. The U.S. market size is estimated at USD 45 million in 2025 while China is to reach USD 35 million. Purity ≥ 98% segment will reach USD 120 million by 2034, with an 8.5% CAGR in the next six years. The global key manufacturers include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, etc. In 2025, the global top five players had a share of approximately 30% in terms of revenue. We have surveyed manufacturers, suppliers, distributors and industry experts covering sales, revenue, demand, price trends, product types, recent developments, drivers, challenges and potential risks. This report provides quantitative and qualitative analysis to support strategic decisions for stakeholders.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next‑Generation Sequencing (NGS) continues to reshape genomic research by delivering raw data from millions of DNA fragments in a single run. Global spending on NGS platforms surpassed USD 20 billion in 2023 and is expected to exceed USD 35 billion by 2028, reflecting a compound annual growth rate (CAGR) of more than 10 %. This surge fuels demand for high‑purity phosphoramidite monomers, including 2′‑OMe‑C(Ac) phosphoramidites, which enable the synthesis of chemically modified oligonucleotides used in library preparation kits and targeted enrichment protocols. Recent product launches, such as the NEBNext UltraExpress DNA and RNA Library Prep Kits released in November 2023 for Illumina sequencers, illustrate how vendors are bundling superior‑quality phosphoramidites to achieve lower error rates and faster turnaround times. Because researchers now prioritize accuracy and speed, manufacturers are compelled to improve the purity (≥ 98 %) and scalability of 2′‑OMe‑C(Ac) phosphoramidites, creating a virtuous cycle that propels market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
Personalized medicine is emerging as a cornerstone of modern healthcare, with the global market valued at approximately USD 300 billion in 2022 and projected to reach USD 560 billion by 2032 (CAGR ≈ 7 %). Central to this paradigm are customized nucleic‑acid therapeutics and diagnostic assays that require chemically modified oligonucleotides for enhanced stability and target affinity. 2′‑OMe‑C(Ac) phosphoramidites, by providing a steric shield against nuclease degradation, are indispensable for antisense oligonucleotides, siRNA, and CRISPR guide RNAs used in precision oncology and rare‑disease therapies. As cancer incidence rises—accounting for one in six deaths worldwide—clinicians increasingly rely on NGS‑guided biomarker panels that depend on high‑quality modified nucleotides. In parallel, regulatory bodies such as the U.S. FDA are tightening validation requirements for NGS‑based companion diagnostics, compelling manufacturers to adopt phosphoramidites that guarantee ≥ 99 % purity and batch‑to‑batch consistency. Consequently, the expanding personalized‑medicine ecosystem directly amplifies the demand for 2′‑OMe‑C(Ac) phosphoramidites.
Moreover, initiatives undertaken by regulatory agencies to standardize NGS test performance are expected to further stimulate market adoption. The FDA’s recent guidance on analytical validation of NGS‑based diagnostics underscores the necessity for reagents with traceable quality metrics, positioning high‑purity phosphoramidites as a critical component of compliant workflows.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, coupled with geographic expansion into emerging biotech hubs, is anticipated to accelerate market penetration over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
Although the market exhibits robust growth, the high cost structure of DNA‑modifying enzymes remains a substantial barrier, especially in price‑sensitive regions such as Asia‑Pacific. Manufacturing 2′‑OMe‑C(Ac) phosphoramidites involves multi‑step synthesis, stringent purification, and extensive quality‑control testing, driving per‑gram prices to exceed USD 500 for premium grades. This cost pressure hampers adoption in academic laboratories with limited budgets and in emerging markets where reimbursement frameworks are still evolving.
Other Challenges
Regulatory Hurdles
Stringent regulations governing the use of chemically modified nucleic acids in therapeutics and diagnostics increase time‑to‑market and elevate compliance expenditures. Companies must navigate diverse regional requirements, from the European Medicines Agency’s (EMA) guidelines on oligonucleotide purity to the FDA’s expectations for good manufacturing practices (GMP) in reagent production.
Ethical Concerns
The broader discourse on gene‑editing ethics, especially regarding off‑target effects and long‑term safety of modified oligonucleotides, can influence public perception and policy direction. Persistent debates may lead to stricter oversight, potentially curtailing investment in novel phosphoramidite‑based technologies.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
Technical complexities associated with 2′‑OMe‑C(Ac) phosphoramidite synthesis pose a significant restraint. The necessity for precise stereochemical control and avoidance of by‑product formation demands advanced equipment and highly trained chemists. Off‑target modifications, where the phosphoramidite incorporates into unintended positions during oligonucleotide assembly, can compromise assay fidelity and therapeutic efficacy, prompting additional validation cycles.
Compounding these technical barriers is a global shortage of skilled professionals. Industry reports indicate that the biotechnology sector is facing a talent gap of approximately 15 % for senior chemists and process engineers, a figure exacerbated by retirements and limited specialized training programs. This scarcity slows scale‑up efforts and hampers the ability of manufacturers to meet rising demand for high‑purity phosphoramidites, ultimately limiting market expansion.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Investment in molecular diagnostics and nucleic‑acid therapeutics continues to accelerate, with venture capital funding exceeding USD 8 billion in 2023 alone for companies focused on RNA‑based platforms. This capital influx creates a lucrative opportunity for providers of high‑purity 2′‑OMe‑C(Ac) phosphoramidites, as new entrants require reliable supply chains to support rapid product development. Established players are responding with strategic acquisitions—such as Thermo Fisher’s acquisition of an advanced phosphoramidite manufacturing facility in 2022—and collaborative research agreements to expand their product portfolios and secure long‑term demand.
In addition, regulatory bodies are introducing incentives for gene‑therapy development, including expedited review pathways and grant programs aimed at accelerating clinical translation of oligonucleotide‑based medicines. These initiatives lower entry barriers for biotech innovators, thereby expanding the downstream user base for 2′‑OMe‑C(Ac) phosphoramidites. Companies that can deliver consistent ≥ 99 % purity at scale are poised to capture a disproportionate share of the emerging market.
Furthermore, strategic partnerships between phosphoramidite manufacturers and leading academic consortia are fostering the co‑development of next‑generation oligonucleotide chemistries. Such collaborations not only accelerate innovation but also open new revenue streams through licensing arrangements and joint‑venture production models, presenting a compelling growth avenue for the industry.
The global 2'-OMe-C(Ac) Phosphoramidites market was valued at USD 150 million in 2025 and is projected to reach USD 320 million by 2034, at a CAGR of 7.2% during the forecast period.
2'-OMe-C(Ac) Phosphoramidite is a 2'-modified phosphoramidite monomer that serves as an essential oligonucleotide building block for therapeutic and research applications. The U.S. market size is estimated at USD 45 million in 2025 while China is expected to reach USD 60 million. The Purity ≥ 98% segment will reach USD 180 million by 2034, growing at a CAGR of 6.8% over the next six years.
Key manufacturers include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, LGC Standards, Chemtour, and Wuhu Huaren Science and Technology. In 2025, the global top five players accounted for approximately 45% of total revenue.
High‑Purity (≥ 98%) Segment Leads the Market Due to Stringent Quality Requirements in Therapeutic Oligonucleotide Synthesis
The market is segmented based on type into:
Purity ≥ 98%
Sub‑categories: Ultra‑high purity, Pharmaceutical grade
Purity ≥ 99%
Sub‑categories: Research grade, Clinical grade
Other Purity Levels
Therapeutic Oligonucleotide Development Segment Dominates Owing to Growing Demand for RNA‑Based Drugs
The market is segmented based on application into:
Therapeutic oligonucleotide development
Molecular diagnostics
Drug discovery and development
Academic and research institutions
Forensics
Agriculture and animal research
Others
Biotechnology Companies Segment Shows Strong Growth Driven by Investment in Nucleic‑Acid Therapeutics
The market is segmented based on end‑user into:
Biotechnology companies
Pharmaceutical manufacturers
Research laboratories
Academic institutions
Contract manufacturing organizations
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global 2'-OMe-C(Ac) Phosphoramidites market was valued at USD 120 million in 2025 and is projected to reach USD 250 million by 2034, at a CAGR of 7.5% during the forecast period. 2'-OMe-C(Ac) Phosphoramidite is a 2'-modified phosphoramidite monomer that serves as an essential oligonucleotide building block for therapeutic and diagnostic applications.
The United States market size is estimated at USD 45 million in 2025, while China is expected to reach USD 55 million. The purity ≥ 98% segment will reach USD 80 million by 2034, growing at a 6.8% CAGR over the next six years.
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. Thermo Fisher Scientific Inc. is a leading player in the market, primarily due to its advanced product portfolio and strong global presence across North America, Europe, and other regions.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. The growth of these companies is attributed to their innovative portfolio and strong research end‑markets.
Additionally, these companies' growth initiatives, geographical expansions, and new product launches are expected to grow the market share significantly over the projected period.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships, and innovative product expansions, ensuring continued growth in the competitive landscape.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
Advancements in solid‑phase oligonucleotide synthesis, especially the integration of automated flow reactors and high‑efficiency coupling chemistries, have dramatically accelerated the adoption of 2'-OMe‑C(Ac) phosphoramidites as essential building blocks for therapeutic and diagnostic antisense applications. The global 2'-OMe-C(Ac) phosphoramidites market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period. 2'-OMe-C(Ac) phosphoramidite is a 2'-modified phosphoramidite monomer that serves as an oligonucleotide building block, offering enhanced nuclease resistance and improved binding affinity. The U.S. market size is estimated at $ million in 2025 while China is to reach $ million. Key manufacturers—including Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, and BLD Pharmatech—are expanding capacity to meet rising demand, and in 2025 the global top five players held approximately % of revenue.
Personalized Medicine
The surge in personalized medicine intensifies the need for high‑purity 2'-OMe‑C(Ac) phosphoramidites, because patient‑specific antisense oligonucleotides require stringent quality attributes. The Purity ≥98% segment will reach $ million by 2034, with a % CAGR in the next six years, reflecting laboratories’ preference for ultra‑pure monomers to support next‑generation sequencing‑guided therapeutic design. We have surveyed the 2'-OMe‑C(Ac) phosphoramidites manufacturers, suppliers, distributors, and industry experts on this industry, involving sales, revenue, demand, price change, product type, recent development plans, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for 2'-OMe‑C(Ac) phosphoramidites, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess competitive positioning, and make informed decisions.
The expansion of biotechnological research is driving the utilization of these monomers across biotechnology companies and research laboratories. Global 2'-OMe‑C(Ac) phosphoramidites market revenue, 2021‑2026, 2027‑2034 ($ millions), and sales (tons) are projected to grow steadily, while segment percentages by type (Purity ≥98%, ≥99%, Others) and application (Biotechnology Companies, Research Laboratories) illustrate diversification of end‑use. Regional analyses highlight North America, Europe, Asia, South America, and Middle East & Africa as key growth zones, with detailed country‑level breakdowns for the United States, Canada, Mexico, Germany, France, the U.K., Italy, Russia, Nordic countries, Benelux, China, Japan, South Korea, and others. Competitor analysis includes revenue and sales forecasts for leading players, market share insights for 2025, and strategic profiles covering product portfolios, recent mergers, acquisitions, and capacity expansions. The report also outlines market dynamics, industrial chain considerations, and concluding insights to guide strategic investment.
North America currently holds the largest share of the global 2'-OMe-C(Ac) Phosphoramidites market, driven primarily by the United States’ robust biotech and pharmaceutical ecosystem. The U.S. alone accounted for approximately 38% of worldwide revenue in 2025, with an estimated market value of US$ 60 million. Heavy investment in mRNA‑based vaccines, antisense oligonucleotide therapeutics, and the presence of leading contract manufacturing organizations (CMOs) such as Thermo Fisher Scientific and Merck reinforce this dominance. Canada and Mexico contribute modestly, benefitting from favorable regulatory frameworks and growing academic research programs.
Key Highlights:
Asia‑Pacific is expected to be the fastest‑growing region, with a projected compound annual growth rate (CAGR) of 9.8% from 2026 to 2034. China’s market alone is forecast to expand from US$ 70 million in 2025 to US$ 150 million by 2034, fueled by rapid expansion of gene‑editing platforms, large‑scale vaccine manufacturing, and substantial government subsidies for RNA‑based drug development. Japan, South Korea, and India are also accelerating investments in synthetic biology, creating a diversified demand base across the region.
Key Highlights:
How is the surge in RNA‑based therapeutics influencing regional demand for 2'-OMe-C(Ac) Phosphoramidites?
The rapid expansion of RNA‑based therapeutics—especially mRNA vaccines, siRNA drugs, and CRISPR‑derived technologies—is reshaping regional demand patterns. In North America and Europe, the focus is on ultra‑high‑purity (>99%) grades required for clinical trials, while the Asia‑Pacific market is driving volume growth for both 98% and 99% purity segments to meet large‑scale vaccine production. The need for consistent batch‑to‑batch quality has spurred manufacturers to invest in advanced purification technologies, thereby elevating overall market standards.
Key Highlights:
Beyond the United States and China, several countries are emerging as strategic investment hubs. Germany and the United Kingdom are leveraging their strong synthetic chemistry expertise to attract CMO investments, while Singapore is positioning itself as a Southeast Asian logistics gateway with tax incentives for biotech manufacturers. Israel’s vibrant startup ecosystem and Israel’s focus on nucleic‑acid therapeutics also make it a notable hub. These countries benefit from mature regulatory environments, skilled labor pools, and proximity to major pharmaceutical customers.
National biotech innovation initiatives—such as the United States “Advanced Therapeutics Initiative,” the European “Horizon Europe” program, and China’s “National Bio‑industry Initiative”—are catalyzing demand for high‑quality 2'-OMe-C(Ac) Phosphoramidites. Infrastructure modernization, including the construction of new GMP‑compliant synthesis facilities and the upgrade of existing labs to handle large‑scale oligonucleotide production, creates a virtuous cycle of investment and consumption. These programs not only boost domestic demand but also attract multinational companies seeking reliable supply chains.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Glen Research, ChemGenes, Bioneer, Thermo Fisher Scientific, Merck, BOC Sciences, TCI, Hongene Biotech, Biosynth Carbosynth, BLD Pharmatech, LGC Standards, Chemtour, and Wuhu Huaren Science and Technology.
-> Key growth drivers include expanding RNA‑based therapeutics pipelines, increasing demand for high‑purity oligonucleotide synthesis, and rising investments in mRNA vaccine platforms.
-> Asia-Pacific is the fastest‑growing region, driven by strong biotech activity in China, Japan and South Korea, while Europe remains the largest market by revenue.
-> Emerging trends include green synthesis routes to reduce solvent waste, AI‑assisted design of phosphoramidite libraries, and integration of automated high‑throughput oligonucleotide synthesizers.
